These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

257 related items for PubMed ID: 10655363

  • 21. In Vitro Comparison of Ertapenem, Meropenem, and Imipenem against Isolates of Rapidly Growing Mycobacteria and Nocardia by Use of Broth Microdilution and Etest.
    Brown-Elliott BA, Killingley J, Vasireddy S, Bridge L, Wallace RJ.
    J Clin Microbiol; 2016 Jun; 54(6):1586-1592. PubMed ID: 27053677
    [Abstract] [Full Text] [Related]

  • 22. Antibiotic susceptibility pattern of rapidly growing mycobacteria.
    Gayathri R, Therese KL, Deepa P, Mangai S, Madhavan HN.
    J Postgrad Med; 2010 Jun; 56(2):76-8. PubMed ID: 20622384
    [Abstract] [Full Text] [Related]

  • 23. Effects of different test conditions on the susceptibility of Mycobacterium fortuitum and Mycobacterium chelonae to amikacin.
    Hansen KT, Clark RB, Sanders WE.
    J Antimicrob Chemother; 1994 Mar; 33(3):483-94. PubMed ID: 8040113
    [Abstract] [Full Text] [Related]

  • 24. In Vitro Susceptibility Testing of a Novel Benzimidazole, SPR719, against Nontuberculous Mycobacteria.
    Brown-Elliott BA, Rubio A, Wallace RJ.
    Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30126964
    [Abstract] [Full Text] [Related]

  • 25. Evaluation of the broth microdilution method using 2,3-diphenyl-5-thienyl-(2)-tetrazolium chloride for rapidly growing mycobacteria susceptibility testing.
    Lee SM, Kim Jm, Jeong J, Park YK, Bai GH, Lee EY, Lee MK, Chang CL.
    J Korean Med Sci; 2007 Oct; 22(5):784-90. PubMed ID: 17982223
    [Abstract] [Full Text] [Related]

  • 26. Activities of linezolid against rapidly growing mycobacteria.
    Wallace RJ, Brown-Elliott BA, Ward SC, Crist CJ, Mann LB, Wilson RW.
    Antimicrob Agents Chemother; 2001 Mar; 45(3):764-7. PubMed ID: 11181357
    [Abstract] [Full Text] [Related]

  • 27. Multisite reproducibility of results obtained by two broth dilution methods for susceptibility testing of Mycobacterium avium complex.
    Woods GL, Williams-Bouyer N, Wallace RJ, Brown-Elliott BA, Witebsky FG, Conville PS, Plaunt M, Hall G, Aralar P, Inderlied C.
    J Clin Microbiol; 2003 Feb; 41(2):627-31. PubMed ID: 12574258
    [Abstract] [Full Text] [Related]

  • 28. In vitro antimicrobial susceptibility testing of rapidly growing mycobacteria using the tablet diffusion method: resistance pattern of Norwegian Mycobacterium fortuitum and Mycobacterium chelonae isolates.
    Hoel T, Casals JB, Eng J.
    APMIS; 1993 Jan; 101(1):27-32. PubMed ID: 8457323
    [Abstract] [Full Text] [Related]

  • 29. In vitro interaction of some drug combinations to inhibit rapidly growing mycobacteria isolates from cats and dogs and these isolates' susceptibility to cefovecin and clofazimine.
    Bennie CJ, To JL, Martin PA, Govendir M.
    Aust Vet J; 2015 Jan; 93(1-2):40-5. PubMed ID: 25622709
    [Abstract] [Full Text] [Related]

  • 30. Topical ciprofloxacin for treating nontuberculous mycobacterial keratitis.
    Hu FR, Luh KT.
    Ophthalmology; 1998 Feb; 105(2):269-72. PubMed ID: 9479286
    [Abstract] [Full Text] [Related]

  • 31. Comparative drug resistance of Mycobacterium abscessus and M. chelonae isolates from patients with and without cystic fibrosis in the United Kingdom.
    Broda A, Jebbari H, Beaton K, Mitchell S, Drobniewski F.
    J Clin Microbiol; 2013 Jan; 51(1):217-23. PubMed ID: 23135941
    [Abstract] [Full Text] [Related]

  • 32. In Vitro Activities of Omadacycline against Rapidly Growing Mycobacteria.
    Shoen C, Benaroch D, Sklaney M, Cynamon M.
    Antimicrob Agents Chemother; 2019 May; 63(5):. PubMed ID: 30858221
    [Abstract] [Full Text] [Related]

  • 33. Topical antibacterial therapy for mycobacterial keratitis: potential for surgical prophylaxis and treatment.
    Abshire R, Cockrum P, Crider J, Schlech B.
    Clin Ther; 2004 Feb; 26(2):191-6. PubMed ID: 15038942
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. In Vitro Susceptibility Testing of Omadacycline against Nontuberculous Mycobacteria.
    Brown-Elliott BA, Wallace RJ.
    Antimicrob Agents Chemother; 2021 Feb 17; 65(3):. PubMed ID: 33288634
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. In Vitro Susceptibility Testing of Eravacycline against Nontuberculous Mycobacteria.
    Brown-Elliott BA, Wallace RJ.
    Antimicrob Agents Chemother; 2022 Sep 20; 66(9):e0068922. PubMed ID: 35943269
    [Abstract] [Full Text] [Related]

  • 38. CI-960 (PD127391 or AM-1091), sparfloxacin, WIN 57273, and isepamicin activity against clinical isolates of Mycobacterium avium-intracellularae complex, M. chelonae, and M. fortuitum.
    Barrett MS, Jones RN, Erwin ME, Koontz FP.
    Diagn Microbiol Infect Dis; 1992 Feb 20; 15(2):169-71. PubMed ID: 1315233
    [Abstract] [Full Text] [Related]

  • 39. Port-site infections by nontuberculous mycobacterium: A retrospective clinico-microbiological study.
    Ghosh R, Das S, De A, Kela H, Saha ML, Maiti PK.
    Int J Mycobacteriol; 2017 Feb 20; 6(1):34-37. PubMed ID: 28317802
    [Abstract] [Full Text] [Related]

  • 40. Infections with rapidly growing mycobacteria: report of 20 cases.
    Sungkanuparph S, Sathapatayavongs B, Pracharktam R.
    Int J Infect Dis; 2003 Sep 20; 7(3):198-205. PubMed ID: 14563223
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.